Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

被引：3
|
作者：
Sunagawa, Shawnalyn W. [1 ,3 ]
Havens, Joshua P. [1 ,2 ]
Podany, Anthony [1 ]
Walker, Bryan [2 ]
Scarsi, Kimberly K. [1 ,2 ]
Bares, Sara H. [2 ]
机构：
[1] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Infect Dis, Omaha, NE 68198 USA
[3] Univ Nebraska Med Ctr, Dept Pharm Practice & Sci, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 12期
关键词：
drug-drug interactions; long-acting cabotegravir/rilpivirine; plasma concentrations; rifamycins;
D O I：
10.1093/ofid/ofad604
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajith K. R. Rajoli
    David J. Back
    Steve Rannard
    Caren Freel Meyers
    Charles Flexner
    Andrew Owen
    Marco Siccardi
    Clinical Pharmacokinetics, 2018, 57 : 255 - 266
  • [22] Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
    Christopoulos, Katerina A.
    Hickey, Matthew D.
    Rana, Aadia
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 11 - 18
  • [23] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajoli, Rajith K. R.
    Back, David J.
    Rannard, Steve
    Meyers, Caren Freel
    Flexner, Charles
    Owen, Andrew
    Siccardi, Marco
    CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 255 - 266
  • [24] Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
    Pintado, Claire
    Delaugerre, Constance
    Molina, Jean-Michel
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [25] Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Hodge, Daryl
    Back, David J.
    Gibbons, Sara
    Khoo, Saye H.
    Marzolini, Catia
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 835 - 853
  • [26] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [27] Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
    Castelli, Alessandro
    Lanzafame, Massimiliano
    Morra, Matteo
    Bertoldi, Marco
    Delama, Andrea
    Fait, Daniela
    Vento, Sandro
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (05) : 283 - 285
  • [28] Long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting: The role of pharmacogenetics
    Cusato, Jessica
    Ferrara, Micol
    Antonucci, Miriam
    Goldan, Razvan
    Soloperto, Sara
    Di Perri, Giovanni
    D'avolio, Antonio
    Calcagno, Andrea
    Bonora, Stefano
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 : 11 - 11
  • [29] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
    Patel, P.
    D'Amico, R.
    Thiagarajah, S.
    Wu, S.
    Elliot, E.
    Polli, J. W.
    Upadhyay, O.
    Van Solingen-Ristea, R.
    Orkin, C.
    Overton, E. T.
    Swindells, S.
    van Wyk, J.
    Bosse, M.
    Vannappagari, V.
    Gray, L.
    SEXUAL HEALTH, 2021, 18 (04) : VI - VI
  • [30] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
    Jonsson-Oldenbuettel, C.
    Ghosn, J.
    Sierra, J. Olalla
    van der Valk, M.
    Lutz, T.
    Belkhir, L.
    van Welzen, B. J.
    Hove, K.
    Ait-Khaled, M.
    DeMoor, R.
    Bontempo, G.
    Latham, C. L.
    Ngenzi, B.
    Okoli, C.
    Gutner, C. A.
    Iyer, S.
    Gill, M.
    Czarnogorski, M.
    D'Amico, R.
    van Wyk, J.
    HIV MEDICINE, 2023, 24 : 193 - 195
12345